Global Age Related Macular Degeneration (AMD) Market Size By Type (Wet AMD, Dry AMD), By Application (Men, Woman), By Region, And Segment Forecasts, 2023 to 2032

The Global Age-Related Macular Degeneration (AMD) Market was valued at USD 11.4 billion in 2023 and is projected to surpass USD 19.5 billion by 2031, growing at a CAGR of 6.9% during the forecast period from 2023 to 2031. The market is driven by the rising prevalence of AMD among the aging population, increasing advancements in treatment options, and the growing awareness about early diagnosis and treatment.

Age-related macular degeneration is a leading cause of vision loss in adults over the age of 50, characterized by damage to the macula, a part of the retina responsible for sharp central vision. As global life expectancy increases, the demand for effective AMD treatments, including anti-VEGF therapies, gene therapy, and regenerative medicine, continues to rise.

Market Drivers

1. Growing Aging Population:

The increasing global geriatric population is one of the primary factors driving the AMD market. With age being a significant risk factor, the growing number of people aged 60 and above has resulted in a higher prevalence of AMD, necessitating effective treatment solutions.

2. Advancements in Treatment Modalities:

Innovations in anti-VEGF therapy, gene therapy, and stem cell therapy are expanding treatment possibilities for AMD patients. The development of sustained-release drug delivery systems is further enhancing patient compliance and treatment efficacy.

3. Rising Awareness and Early Diagnosis Initiatives:

Government and non-profit organizations are actively conducting awareness campaigns to encourage early AMD detection, leading to increased demand for diagnostic tools and early-stage therapies.

Market Restraints

1. High Cost of AMD Treatments:

The high cost of AMD therapies, particularly anti-VEGF injections like Lucentis, Eylea, and Beovu, poses a significant barrier to treatment accessibility, especially in developing economies.

2. Lack of Reimbursement Policies in Some Regions:

While insurance coverage and reimbursement for AMD treatments are available in many developed nations, several low-income and middle-income countries lack comprehensive healthcare coverage, restricting patient access to advanced treatments.

Market Opportunities

1. Emerging Markets and Untapped Regions:

Developing regions such as Asia-Pacific, Latin America, and the Middle East & Africa are witnessing a rise in AMD cases due to aging demographics and lifestyle changes. Expansion into these markets presents significant growth opportunities for industry players.

2. Increasing Investment in Gene and Cell Therapy:

The emergence of gene therapy and stem cell-based regenerative treatments is gaining traction as potential long-term solutions for AMD. Companies investing in these cutting-edge innovations are expected to gain a competitive edge in the market.

Market Segmentation

By Type Insights

Dry AMD: The most common form, accounting for approximately 85-90% of total AMD cases. Dry AMD progresses slowly, leading to gradual vision loss over time.

Wet AMD: A more severe and less common form, wet AMD causes rapid vision loss due to abnormal blood vessel growth under the retina.

By Treatment Insights

Anti-VEGF Therapy: The largest segment, with drugs like Lucentis, Eylea, and Beovu dominating the market.

Photodynamic Therapy (PDT): Used as a secondary treatment option, particularly in cases where anti-VEGF therapy is insufficient.

Gene and Stem Cell Therapy: Emerging as high-potential innovations aimed at reversing AMD progression.

By Distribution Channel Insights

Hospitals & Specialty Clinics: The dominant segment due to the availability of advanced diagnostic tools and treatment facilities.

Retail Pharmacies: Expected to witness growth with the rising availability of prescription drugs for AMD.

Online Pharmacies: Gaining traction due to e-commerce expansion and increased home delivery of prescription medicines.

Market by Regional Insights

1. North America:

Largest market share in 2023 due to high healthcare spending, strong R&D investment, and advanced treatment options.

2. Europe:

Significant market presence, driven by an aging population, increasing government healthcare initiatives, and rising AMD awareness.

3. Asia-Pacific:

The fastest-growing region, fueled by expanding healthcare infrastructure, increasing cases of AMD, and improving access to advanced therapies.

4. Latin America & Middle East & Africa:

These regions offer growth potential due to rising life expectancy, increasing healthcare investments, and expanding awareness campaigns.

Competitive Scenario

Key players in the Global AMD Market include:

Regeneron Pharmaceuticals, Inc.

Novartis AG

Bayer AG

Roche Holdings AG

AbbVie Inc.

Pfizer Inc.

Bausch + Lomb

Apellis Pharmaceuticals

Alcon

Outlook Therapeutics

These companies are focusing on new drug developments, strategic collaborations, and acquisitions to strengthen their market position.

Key Market Developments

2023: Novartis launched a new sustained-release anti-VEGF therapy designed to reduce injection frequency for AMD patients.

2023: Regeneron expanded its pipeline with a next-generation gene therapy approach for treating wet AMD.

2024: Roche introduced an AI-driven diagnostic tool for early AMD detection, improving patient outcomes.

2024: Bayer AG partnered with a biotech firm to develop a regenerative medicine solution for AMD.

Scope of Work – Global Age-Related Macular Degeneration (AMD) Market

Report Metric Details

Market Size (2023) USD 11.4 billion

Projected Market Size (2031) USD 19.5 billion

CAGR (2023-2031) 6.9%

Key Segments Type (Dry AMD, Wet AMD), Treatment (Anti-VEGF Therapy, PDT, Gene & Stem Cell Therapy), Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies)

Leading Region North America

Key Players Regeneron, Novartis, Bayer, Roche, AbbVie, Pfizer, Bausch + Lomb, Apellis Pharmaceuticals

FAQs

1. What is the current market size of the Age-Related Macular Degeneration (AMD) market?

The Global Age-Related Macular Degeneration (AMD) Market was valued at USD 11.4 billion in 2023.

2. What is the major growth driver of the AMD market?

The rising geriatric population and increasing prevalence of AMD worldwide are the primary growth drivers.

3. Which is the largest region in the AMD market during the forecast period?

North America holds the largest market share due to high healthcare investment, advanced treatment availability, and strong R&D initiatives.

4. Which segment accounted for the largest market share in the AMD market?

The Anti-VEGF therapy segment accounted for the largest market share, with drugs like Eylea, Lucentis, and Beovu leading the industry.

5. Who are the key market players in the AMD market?

Key players include Regeneron Pharmaceuticals, Novartis AG, Bayer AG, Roche Holdings AG, AbbVie Inc., Pfizer Inc., Bausch + Lomb, and Apellis Pharmaceuticals.

This report provides an in-depth analysis of the Global Age-Related Macular Degeneration (AMD) Market, offering valuable insights into market trends, drivers, restraints, opportunities, and competitive dynamics.